By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists generally agree that VHT offers stability and lower fees, but its high concentration in a few mega-cap stocks exposes it to specific risks. PBE, on the other hand, provides more diversification but carries higher fees and potential liquidity risks. The 'core vs. satellite' choice depends on the investor's time horizon and risk capacity.
Risk: High concentration in a few mega-cap stocks for VHT, and potential liquidity crunch or value destruction from M&A for PBE.
Opportunity: Potential alpha from PBE through successful M&A or FDA approvals, and stable, low-cost exposure to healthcare through VHT.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) offers a focused, high-momentum approach to the biotechnology sector, while the Vanguard Health Care ETF (NYSEMKT:VHT) provides broad, low-cost exposure across the entire healthcare landscape -- from pharmaceutical giants to equipment makers to healthcare providers.
| Metric | PBE | VHT | |---|---|---| | Issuer | Invesco | Vanguard | | Expense ratio | 0.58% | 0.09% | | 1-year return (as of July 29, 2026) | 40.88% | 27.85% | | Dividend yield | 1.73% | 1.58% | | Beta | 0.79 | 0.57 | | AUM | $277.9 million | $20.4 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Cost is a major differentiator here. VHT charges just 0.09% a year, versus 0.58% for PBE. The funds’ dividend yields are in the same ballpark, with VHT paying 1.58% and PBE paying 1.73%
| Metric | PBE | VHT | |---|---|---| | Max drawdown (5 yr) | (37.84%) | (17.71%) | | Growth of $1,000 over 5 years (total return) | $1,238 | $1,308 |
Launched in 2004, VHT uses a passive management approach to track the broader healthcare sector and holds 423 stocks. Its largest positions include Eli Lilly (NYSE:LLY) at 14.2%, Johnson & Johnson (NYSE:JNJ) at 8.9%, and AbbVie (NYSE:ABBV) at 6.5%.
PBE takes a narrower path, holding 31 U.S. companies chosen for price momentum, earnings growth, and management quality. Its top holdings include Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.2%, Biogen (NASDAQ:BIIB) at 5.1%, and Amgen (NASDAQ:AMGN) at 4.97%.
For more guidance on ETF investing, check out the full guide at this link.
What are you looking for in a healthcare ETF -- breadth or targeted bets? That’s the first question to ask when deciding between these two funds.
VHT's 423 holdings span the entire healthcare industry -- pharma, insurers, device makers, and hospital operators -- but that breadth is a bit deceptive. Like most cap-weighted funds, VHT still concentrates its bets at the top: Eli Lilly, Johnson & Johnson, and AbbVie alone make up nearly 30% of the portfolio. So while a mid-cap device maker's stumble won't dent returns much, a stumble at Eli Lilly -- its largest holding at 14% -- would still be felt. Still, VHT’s broad portfolio, paired with a 0.09% expense ratio, makes it a low-drama way to stay invested in a sector that tends to hold up reasonably well even when the overall market wobbles.
PBE is a different story. With just 31 holdings screened for growth and momentum, it's making a more targeted bet on biotech innovation. That’s why it’s been able to boast a stellar 40.9% one-year return -- and it’s also why the fund has experienced a far deeper 5-year maximum drawdown. Biotech stocks live and die by binary events like FDA decisions and trial data, which help fuel both rallies and crashes.
Both approaches have merit depending on an investor’s goals and strategy. VHT is the better fit for investors who want steady, lower-cost exposure to a broader healthcare theme and can live with some large-cap concentration risk at the top of the portfolio. PBE suits investors with a higher risk tolerance who are specifically chasing biotech's growth potential, and who are willing to stomach sharper swings -- and a steeper expense ratio -- to get it.
Before you buy stock in Vanguard World Fund - Vanguard Health Care ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard World Fund - Vanguard Health Care ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,081! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,166,221!
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 30, 2026. *
Andy Gould has positions in AbbVie and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends AbbVie, Amgen, Eli Lilly, and Vertex Pharmaceuticals. The Motley Fool recommends Biogen and Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"VHT remains the better risk-adjusted healthcare ETF for most investors despite PBE's recent outperformance."
VHT's 0.09% expense ratio and 423 holdings make it the superior long-term vehicle for healthcare exposure versus PBE's 0.58% fee and 31-stock biotech concentration. The article's 1-year return snapshot (PBE 40.88% vs VHT 27.85% as of July 2026) is misleading; over 5 years VHT actually delivered higher cumulative returns ($1,308 vs $1,238) with far lower max drawdown (-17.71% vs -37.84%). Biotech's binary FDA-driven volatility remains unaddressed. VHT's top-heavy 30% in LLY/JNJ/ABBV still offers better risk-adjusted exposure to steady pharma, devices, and providers than PBE's momentum bet.
If we are entering a new biotech supercycle driven by gene editing, AI-drug discovery, and GLP-1 successors, PBE's concentrated high-momentum approach could materially outperform VHT for the next 3-5 years despite higher fees and volatility.
"VHT's current performance is heavily skewed by GLP-1 exposure, masking the underlying volatility of the broader healthcare sector it claims to represent."
The article presents a classic 'core vs. satellite' choice, but it misses the primary risk factor: interest rate sensitivity. VHT is a defensive play on aging demographics and stable cash flows, while PBE is essentially a leveraged bet on speculative R&D and M&A activity. The 14.2% concentration in Eli Lilly within VHT makes it a proxy for the GLP-1 obesity drug cycle, not a diversified healthcare play. Investors should be wary: if cost-of-capital remains elevated, PBE’s 31-stock portfolio is vulnerable to a liquidity crunch, whereas VHT’s reliance on mega-cap pharma leaves it exposed to potential Medicare price negotiation headwinds that the article completely ignores.
If we are entering a period of rapid innovation in gene editing and oncology, PBE’s concentrated momentum strategy could significantly outperform as large-cap incumbents struggle to innovate internally and turn to M&A to fill their pipelines.
"VHT and PBE are not actually comparable on diversification grounds—VHT is a concentrated mega-cap pharma fund masquerading as broad healthcare exposure, while PBE is a legitimate biotech bet, making the choice fundamentally about sector conviction, not risk management."
This article presents a false binary. VHT's 0.09% expense ratio is genuinely compelling, but the article obscures a critical fact: VHT's top 3 holdings (LLY, JNJ, ABBV) represent ~30% of the portfolio, meaning you're not getting 423 diversified bets—you're getting a mega-cap pharma play with a long tail. PBE's 40.88% one-year return is real, but the 37.84% max drawdown and 0.58% fee create a compounding drag that the article undersells. The real miss: neither fund captures the fastest-growing healthcare subsectors (specialty pharma, diagnostics, digital health) meaningfully. This is a choice between 'boring mega-cap stability' and 'binary biotech volatility'—neither is obviously superior without knowing the investor's actual time horizon and risk capacity.
If biotech innovation cycles accelerate (AI-driven drug discovery, GLP-1 expansion beyond obesity), PBE's concentrated 31-stock bet could outrun VHT's drag by 500+ bps annually for a decade, making the 0.58% fee trivial relative to alpha capture.
"VHT's broad, low-cost exposure will deliver steadier risk-adjusted returns than PBE's high-beta biotech concentration."
While the article promotes VHT as the safer, cheaper choice, the real risk is that health care ETFs act like a sector bet on macro stability. PBE’s 31-stock biotech focus can capture big upside from FDA approvals or trial data, but it also means outsized downside in a bad data day or pricing reset. The observed 5-year drawdown of 37.84% and higher beta (0.79) imply more volatility under stress, which could overwhelm its one-year run if a volatility spike hits, especially with higher fees. In a risk-off regime, breadth and cost win—VHT looks more durable.
Biotech catalysts can deliver outsized alpha, and PBE’s 31-name focus may outperform VHT when trial data surprises or FDA decisions land positively. If rates stabilize and risk appetite returns, that concentrated exposure could dwarf broad-healthcare gains, making PBE the better lever to alpha, not merely a risk takeaway.
"VHT's GLP-1 concentration creates hidden single-stock risk that both panelists underweight relative to PBE."
Gemini and Claude both flag VHT's 30% LLY/JNJ/ABBV concentration yet treat it as stable mega-cap ballast. They miss that LLY alone now drives ~40% of the GLP-1 obesity wave; any Medicare negotiation expansion or trial setback in tirzepatide successors would cascade through VHT far harder than through PBE's diversified biotech basket.
"PBE holds the M&A targets that VHT's mega-caps must acquire to survive, creating an asymmetric upside that outweighs the fee and drawdown risks."
Grok, you are right about the LLY concentration, but you and Gemini are both ignoring the 'M&A premium' inherent in PBE. Big Pharma is currently cash-rich and pipeline-poor, forced to acquire PBE’s holdings at massive premiums to sustain growth. VHT is essentially buying the acquirers, while PBE holds the targets. If the FTC antitrust environment softens, PBE’s 31-stock basket becomes a collection of M&A lottery tickets, rendering your drawdown concerns secondary to potential acquisition-driven alpha.
"M&A premiums are real, but PBE's concentrated targets face binary execution risk that VHT's acquirers structurally avoid."
Gemini's M&A premium thesis is clever but assumes FTC softening without evidence. More critically: PBE's 31-stock concentration means a single failed acquisition or regulatory block (say, Novo on a major target) could crater the portfolio faster than broad VHT. The 'lottery ticket' framing obscures that most biotech M&A destroys acquirer shareholder value post-close. VHT's mega-cap acquirers have survived decades of bad deals; PBE's targets haven't.
"M&A premium is fragile; regulatory risk and post-close value destruction undermine PBE's ability to deliver durable alpha."
Gemini, your M&A premium thesis hinges on a permissive regulatory backdrop that may not hold. Antitrust risk is higher now, and even with deals, post-close value destruction in biotech M&A is common. In stress markets, liquidity frictions could turn PBE into a bid-target lottery with forced sales, while VHT’s mega-cap bias risks price negotiations biting big pharma. Alpha from PBE needs a durable, not just deal flow, path.
The panelists generally agree that VHT offers stability and lower fees, but its high concentration in a few mega-cap stocks exposes it to specific risks. PBE, on the other hand, provides more diversification but carries higher fees and potential liquidity risks. The 'core vs. satellite' choice depends on the investor's time horizon and risk capacity.
Potential alpha from PBE through successful M&A or FDA approvals, and stable, low-cost exposure to healthcare through VHT.
High concentration in a few mega-cap stocks for VHT, and potential liquidity crunch or value destruction from M&A for PBE.